99 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
A treatment and prophylaxis, and the potential efficacy and clinical benefits of, and market for, such product candidates. The words "believe," "may
8-K
EX-99.1
g54held022v6fi1b6
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
EX-99.1
cwmm5e xa9mxsz
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
8-K
EX-99.1
d5ajhbmvcshwup93jn
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
8-K
EX-99.2
y1ibc00x2jx phk1j
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
sttkk4ppwh0tv75
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
EX-1.1
6mrbryzbev
5 May 21
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-99.2
kak7u8f7 u3nfw
2 Oct 20
Other Events
8:00am
8-K
EX-1.1
0f032mo57ve
27 Aug 20
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-1.1
2haeaxwrtd1
2 Jul 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
4ltuwkgeknyfpep5evb1
13 Mar 20
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market
4:44pm
8-K
EX-10.2
opggjw949 3obi
4 Mar 20
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
5:09pm
8-K
EX-10.1
5qtqefwixs8cuw7r7pt2
4 Mar 20
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
5:09pm